<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Evol Med Public Health</journal-id><journal-id journal-id-type="iso-abbrev">Evol Med Public Health</journal-id><journal-id journal-id-type="pmc-domain-id">2262</journal-id><journal-id journal-id-type="pmc-domain">emph</journal-id><journal-id journal-id-type="publisher-id">emph</journal-id><journal-title-group><journal-title>Evolution, Medicine, and Public Health</journal-title></journal-title-group><issn pub-type="epub">2050-6201</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12783088</article-id><article-id pub-id-type="pmcid-ver">PMC12783088.1</article-id><article-id pub-id-type="pmcaid">12783088</article-id><article-id pub-id-type="pmcaiid">12783088</article-id><article-id pub-id-type="doi">10.1093/emph/eoaf038</article-id><article-id pub-id-type="publisher-id">eoaf038</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Exploring Eco-Evo Applications In Cancer</subject><subj-group subj-group-type="category-toc-heading"><subject>Original Research Article</subject></subj-group></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00860</subject><subject>AcademicSubjects/SCI01130</subject></subj-group></article-categories><title-group><article-title>Divergent evolution of hepatocellular carcinoma genomes in chimpanzees and humans</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kang</surname><given-names initials="L">Lin</given-names></name><aff>
<institution>Division of Biomedical Affairs and Research</institution>, <institution>Edward Via College of Osteopathic Medicine</institution>, <addr-line>Monroe, LA 71203</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Center for One Health Research; VA-MD Regional College of Veterinary Medicine</institution>, <addr-line>Blacksburg, VA 24060</addr-line>, <country country="US">USA</country></aff><aff>
<institution>College of Pharmacy, University of Louisiana Monroe</institution>, <addr-line>Monroe, LA 71203</addr-line>, <country country="US">USA</country></aff><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation" degree-contribution="equal">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="lead">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="equal">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="equal">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software" degree-contribution="equal">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation" degree-contribution="equal">Validation</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Michalak</surname><given-names initials="K">Katarzyna</given-names></name><aff>
<institution>Division of Biomedical Affairs and Research</institution>, <institution>Edward Via College of Osteopathic Medicine</institution>, <addr-line>Monroe, LA 71203</addr-line>, <country country="US">USA</country></aff><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="equal">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="equal">Methodology</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Varghese</surname><given-names initials="R">Robin</given-names></name><aff>
<institution>Center for One Health Research; VA-MD Regional College of Veterinary Medicine</institution>, <addr-line>Blacksburg, VA 24060</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Division of Biomedical Affairs and Research</institution>, <institution>Edward Via College of Osteopathic Medicine</institution>, <addr-line>Blacksburg, VA 24061</addr-line>, <country country="US">USA</country></aff><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="equal">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="equal">Writing - original draft</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Anandakrishnan</surname><given-names initials="R">Ramu</given-names></name><aff>
<institution>Center for One Health Research; VA-MD Regional College of Veterinary Medicine</institution>, <addr-line>Blacksburg, VA 24060</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Division of Biomedical Affairs and Research</institution>, <institution>Edward Via College of Osteopathic Medicine</institution>, <addr-line>Blacksburg, VA 24061</addr-line>, <country country="US">USA</country></aff><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization" degree-contribution="supporting">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="supporting">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="equal">Methodology</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dick</surname><given-names initials="EJ">Edward J</given-names><suffix>Jr</suffix></name><aff>
<institution>Southwest National Primate Research Center, Texas Biomedical Research Institute</institution>, <addr-line>San Antonio, TX 78245</addr-line>, <country country="US">USA</country></aff><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization" degree-contribution="equal">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources" degree-contribution="equal">Resources</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abd Elmageed</surname><given-names initials="Z">Zakaria</given-names></name><aff>
<institution>Division of Biomedical Affairs and Research</institution>, <institution>Edward Via College of Osteopathic Medicine</institution>, <addr-line>Monroe, LA 71203</addr-line>, <country country="US">USA</country></aff><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization" degree-contribution="equal">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis" degree-contribution="equal">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="equal">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="equal">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="equal">Writing - original draft</role></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4890-8985</contrib-id><name name-style="western"><surname>Michalak</surname><given-names initials="P">Pawel</given-names></name><aff>
<institution>Division of Biomedical Affairs and Research</institution>, <institution>Edward Via College of Osteopathic Medicine</institution>, <addr-line>Monroe, LA 71203</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Center for One Health Research; VA-MD Regional College of Veterinary Medicine</institution>, <addr-line>Blacksburg, VA 24060</addr-line>, <country country="US">USA</country></aff><aff>
<institution>Institute of Evolution, University of Haifa</institution>, <addr-line>Haifa 3498838</addr-line>, <country country="IL">Israel</country></aff><xref rid="cor1" ref-type="corresp"/><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization" degree-contribution="lead">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation" degree-contribution="equal">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology" degree-contribution="equal">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration" degree-contribution="lead">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources" degree-contribution="equal">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision" degree-contribution="equal">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft" degree-contribution="equal">Writing - original draft</role></contrib></contrib-group><author-notes><corresp id="cor1">Corresponding author. Edward Via College of Osteopathic Medicine, Monroe, LA 71203, USA. E-mail: <email>pmichalak@vcom.edu</email></corresp></author-notes><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-12-15"><day>15</day><month>12</month><year>2025</year></pub-date><volume>14</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">504687</issue-id><fpage>1</fpage><lpage>14</lpage><history><date date-type="received"><day>28</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>06</day><month>11</month><year>2025</year></date><date date-type="accepted"><day>08</day><month>12</month><year>2025</year></date><date date-type="corrected-typeset"><day>09</day><month>1</month><year>2026</year></date></history><pub-history><event event-type="pmc-release"><date><day>15</day><month>12</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>10</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-10 00:25:12.930"><day>10</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025. Published by Oxford University Press on behalf of the Foundation for Evolution, Medicine, and Public Health.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="eoaf038.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="eoaf038.pdf"/><abstract><title>Abstract</title><sec id="sec3"><title>Background and objectives</title><p>Somatic mutation patterns in cancer remain largely unexplored outside humans, despite their significance for aging and oncogenesis. Chimpanzees (<italic toggle="yes">Pan troglodytes</italic>), sharing &gt;98% genomic similarity with humans, display markedly different cancer spectra. To gain comparative insights into cancer susceptibility and resistance, we sequenced chimpanzee hepatocellular carcinoma (HCC) genomes and analyzed their mutational profiles alongside human counterparts.</p></sec><sec id="sec4"><title>Methodology</title><p>HCC and matched non-cancerous tissues from five chimpanzees were examined using histopathology, immunohistochemistry (&#946;-catenin, ARID1A, TSC2, FAP, vimentin, TGF-&#946;), whole-genome sequencing (one pair), and whole-exome sequencing (four pairs). Somatic variants were identified with GATK MuTect2, annotated with Ensembl VEP, and analyzed for functional enrichment. Comparative analyses were performed with subsets of human HCC datasets (TCGA, ICGC) including <italic toggle="yes">TSC2</italic>-positive and <italic toggle="yes">TSC2</italic>-negative cases.</p></sec><sec id="sec5"><title>Results</title><p>Chimpanzee HCCs exhibited histological and immunohistochemical features similar to human tumors but displayed sharply divergent genomic landscapes. Chimpanzee tumors carried significantly higher coding mutation loads (mean 5632 per sample vs. 96&#8211;275 in humans). Non-synonymous <bold><italic toggle="yes">TSC2</italic></bold> mutations occurred in 80% of chimpanzees, versus ~7% in human HCC, suggesting a species-specific oncogenic pathway linked to the scirrhous subtype. Additional recurrently mutated genes included <bold><italic toggle="yes">ARID1A</italic>, <italic toggle="yes">FAT1&#8211;4</italic>, <italic toggle="yes">TP53</italic>,</bold> and <bold><italic toggle="yes">FGA</italic></bold>. Despite greater heterogeneity in chimpanzee tumors, humans showed stronger enrichment of non-synonymous single nucleotide variants, implying more intense positive selection. Shared alterations across species involved canonical drivers such as <bold><italic toggle="yes">TP53</italic>, <italic toggle="yes">CTNNB1</italic>, <italic toggle="yes">FAT4</italic>,</bold> and <bold><italic toggle="yes">TTN</italic>.</bold></p></sec><sec id="sec6"><title>Conclusions and implications</title><p>Chimpanzee HCCs are defined by high mutational burden and frequent <bold><italic toggle="yes">TSC2</italic></bold> alterations, contrasting with the more selectively constrained mutation spectrum of human HCC. Divergent evolutionary patterns highlight species-specific oncogenic routes while underscoring conserved pathways. Comparative primate cancer genomics offers novel insights into cancer evolution, biomarkers, and therapeutic targets.</p></sec></abstract><kwd-group><kwd>comparative cancer genomics</kwd><kwd>cancer evolution</kwd><kwd>primate genomics</kwd><kwd>somatic mutations</kwd></kwd-group><counts><page-count count="14"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec7"><title>INTRODUCTION</title><p>As a consequence of multicellularity, cancer is a ubiquitous disease among metazoans [<xref rid="ref1" ref-type="bibr">1</xref>]. Selection pressure for molecular mechanisms of natural cancer resistance is very strong because an animal that develops cancer prematurely will leave less or no progeny. A comparative genomics approach to studying cancer across diverse phylogenetic lineages offers significant insights into alternative variations within and among immune-oncologic pathways, which extend beyond those observed in humans. This can greatly advance the field of precision oncology, including the development of targeted therapies.</p><p>This approach applied to whole genome data from various mammalian species has already begun to provide striking examples of genetic novelties contributing to cancer resistance, as well as &#8220;Peto&#8217;s paradox,&#8221; or the lack of correlation between body size and cancer risk among mammalian species [<xref rid="ref2" ref-type="bibr">2</xref>]. Peto&#8217;s paradox goes against the prediction that large animals have more cells in their bodies, tend to live longer, and thus should have a statistically higher risk of developing malignancy [<xref rid="ref3" ref-type="bibr">3</xref>]. Remarkably, the elephant genome encodes 19 extra copies of the tumor suppressor gene <italic toggle="yes">TP53</italic>, which coincides with a hyperactive TP53 signaling pathway and the evolution of large body size [<xref rid="ref4" ref-type="bibr">4</xref>, <xref rid="ref5" ref-type="bibr">5</xref>]. Whales, including the longest-lived bowhead whale (<italic toggle="yes">Balaena mysticetus</italic>) with its lifespan exceeding 200&#160;years, have evolved an alternative mechanism to cope with increased cancer risk through adaptive changes to DNA repair genes [<xref rid="ref6" ref-type="bibr">6</xref>]. Species- or lineage-unique genetic innovations related to cancer suppression have been found in many other long-lived and unusually cancer-resistant mammalian species, such as naked mole rat (<italic toggle="yes">Heterocephalus glaber</italic>) [<xref rid="ref7" ref-type="bibr">7</xref>], blind mole rat (<italic toggle="yes">Spalax ehrenbergi</italic>) [<xref rid="ref8" ref-type="bibr">8</xref>], Brandt&#8217;s bat (<italic toggle="yes">Myotis brandtii</italic>) [<xref rid="ref9" ref-type="bibr">9</xref>], and possibly even primates [<xref rid="ref10" ref-type="bibr">10</xref>].</p><p>Despite these advances, relatively few studies have examined the evolutionary divergence of cancer-related genes specifically between humans and chimpanzees, the two closely related species with strikingly different cancer susceptibilities. Comparative genomic scans have identified several loci under positive selection in the human lineage, including tumor suppressor and DNA repair genes [<xref rid="ref10" ref-type="bibr">10</xref>, <xref rid="ref11" ref-type="bibr">11</xref>], and revealed structural and regulatory divergence in cancer-associated loci such as <italic toggle="yes">BRCA1</italic> [<xref rid="ref12" ref-type="bibr">12</xref>], <italic toggle="yes">ELAC2</italic> [<xref rid="ref13" ref-type="bibr">13</xref>], and <italic toggle="yes">FHIT</italic> [<xref rid="ref14" ref-type="bibr">14</xref>]. These findings suggest that subtle evolutionary modifications in genes involved in genome stability, cell-cycle control, and DNA repair may contribute to species-specific differences in cancer vulnerability. Moreover, cross-species expression analyses indicate that human-specific amino acid changes and regulatory rewiring in key pathways may alter biochemical and oncogenic properties relative to chimpanzees [<xref rid="ref15" ref-type="bibr">15</xref>].</p><p>In contrast to interspecies germline divergence in cancer-related genes as represented by reference genomes, differences in the landscapes of somatic mutations in cancer are largely unknown outside of our own species. Despite widely variable life histories among mammalian species, including variation of around 30-fold in lifespan and around 40&#8201;000-fold in body mass, the somatic mutation load in non-cancerous tissues at the end of lifespan remained relatively constant, varying only by a factor of around three [<xref rid="ref16" ref-type="bibr">16</xref>]. Oncogenic phenomena are common in mammals and exhibit substantial differences in cancer mortality across major mammalian orders [<xref rid="ref17" ref-type="bibr">17</xref>]. The phylogenetic distribution of cancer mortality appears to be associated with diet, with carnivorous mammals, particularly those that consume other mammals, experiencing the highest cancer-related mortality [<xref rid="ref17" ref-type="bibr">17</xref>]. Cancer rates among humans are relatively high and increasing, with the three most common cancer types being skin, lung, and breast carcinomas [<xref rid="ref1" ref-type="bibr">1</xref>].</p><p>In comparison, cancer has been uncommon in nonhuman primates, particularly in chimpanzees (<italic toggle="yes">Pan troglodytes</italic>), although it has become increasingly manifest as primate colonies aged [<xref rid="ref18" ref-type="bibr">18</xref>, <xref rid="ref19" ref-type="bibr">19</xref>]. The most common chimpanzee cancers are uterine leiomyomas, followed by hepatocellular carcinomas (HCCs) and ovarian stromal tumors [<xref rid="ref18" ref-type="bibr">18</xref>], but to date no attempts have been made to characterize those at the molecular or genomic level and compare them with similar human malignancies. While large-scale screens for somatic mutations in human cancer genomes are currently in routine use, there has been little traction for collecting DNA sequences from non-human primate cancers, mostly due to their rarity. Here we highlight genomic changes related to HCCs and divergent evolution patterns of the cancer genomes in chimpanzees and humans.</p><p>Human HCC is the most common type of primary liver cancer and the second leading cause of cancer-related deaths worldwide [<xref rid="ref20" ref-type="bibr">20</xref>]. Chronic viral hepatitis (Hepatitis B virus/HBV and Hepatitis C virus/HCV) remains a major cause of liver cancers in humans, and the relative prevalence of HCC among captive chimpanzees may be associated with their exposure to HBV and HCV infections, as well as <italic toggle="yes">Schistosoma mansoni</italic> and human immunodeficiency virus (HIV) co-infections [<xref rid="ref21" ref-type="bibr">21</xref>, <xref rid="ref22" ref-type="bibr">22</xref>]. Chimpanzees are the only non-human primates that can develop acute and chronic HBV and HCV infections and associated hepatitis. For this reason, they were considered the most important animal model for viral hepatitis research before a ban on chimpanzee research was enforced [<xref rid="ref23" ref-type="bibr">23</xref>, <xref rid="ref24" ref-type="bibr">24</xref>].</p></sec><sec id="sec8"><title>METHODS</title><sec id="sec9"><title>Chimpanzee samples</title><p>This study was conducted in accordance with the Institutional Animal Care and Use Committee (IACUC) guidelines, approved by The Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX (IACUC #1516 PT). Five chimpanzees diagnosed with HCC were included in the study (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>). The average age of the animals was 33.8&#8201;&#177;&#8201;9.2 years, with 40% (2/5) being female and 60% (3/5) male. The animals weighed an average of 59.02&#8201;&#177;&#8201;5.6&#160;kg before their termination. All animals had confirmed diagnoses of HCC, with two exhibiting metastases to the lungs, and one (20%) additionally showing metastasis to the kidneys and lymph nodes. The liver cancer diagnosis was confirmed microscopically by a pathologist. For each liver cancer sample, kidney tissues from the same animal were collected as normal samples, except in one case of metastasis, where heart tissue was used as the normal sample. One individual tested positive for HBV and HIV, while four tested positive for HCV (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>).</p></sec><sec id="sec10"><title>Immunostaining of chimp tissues</title><p>Formalin-fixed paraffin-embedded liver and its matched tissue blocks of adult chimpanzees were obtained from Texas Biomedical Research Institute, Southwest National Primate Research Center, San Antonio, TX. The tissues provided were examined and confirmed as HCC by a cytopathologist using H&amp;E staining and specific HCC markers (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref> and <xref rid="sup1" ref-type="supplementary-material">Fig. S1</xref>). The immunostaining of tissues was performed as per our previous reports [<xref rid="ref25" ref-type="bibr">25</xref>, <xref rid="ref26" ref-type="bibr">26</xref>]. Briefly, chimpanzee tissues were cut into 5&#160;&#956;m thick sections. The tissue slides were de-waxed in a series of xylene solutions and rehydrated in descending dilutions of ethanol. The tissue slides heated for 20&#160;min in EDTA buffer solution at pH&#160;8.0. The tissue slides incubated in 3% peroxide to block endogenous peroxidases activity. After washing and blocking steps, the tissue slides were incubated with anti-&#946;-catenin, anti-Tuberin/TSC2, anti-ARID1A/BAF250A, anti-FAB, anti-Vimentin, and anti- TGF-&#946; primary antibodies for 60&#160;min at 37&#176;C (Cell Signaling Technology, Danvers, MA, USA). Other tissue slides were incubated with PBS and kept as a negative control. Sections were washed and incubated with the appropriate biotinylated secondary antibodies (Dako, Carpinteria, CA, USA), followed by incubation with Avidin DH and biotinylated horseradish peroxidase H complex according to the standard protocol (Vector Laboratories, Burlingame, CA, USA). After washing, the reaction was visualized with 3,3&#8242;-Diaminobenzidine. Tissue sections were counterstained with hematoxylin, dehydrated, and cleared in xylene then mounted in mounting medium. The developed protein staining was acquired using an AmScope microscope with camera (AmScope, Irvine CA). The tissue slides were blindly examined and expressed as histochemical score (HCS) as reported [<xref rid="ref27" ref-type="bibr">27</xref>]. The immunostaining of each protein was considered negative when HCS is 0, weak expression (1&#8211;2), moderate expression (3&#8211;5), and strong expression (6&#8211;8).</p></sec><sec id="sec11"><title>DNA extraction and sequencing</title><p>DNA was extracted from 10 FFPE tissues using the QIAamp FFPE Advanced kit (Cat# 56704, Qiagen, Germantown, MD) following the manufacturer&#8217;s instructions. The quantity of DNA was assessed using Qubit 4 Fluorometer (ThermoFisher, Waltham, MA), and purity was examined using 2100 Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA). Approximately 1.2&#160;&#956;g of DNA from each sample was used for sequencing. WGS was performed on one sample pair, while WES was conducted on four sample pairs at Genewiz (South Plainfield, NJ) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S3</xref>). Briefly, the SureSelect Human All Exon V6 panel (Agilent Technologies, Inc.) was utilized for whole-exome capture. Previous studies have demonstrated the feasibility of using human-based capture probes for sequencing the exomes of non-human primates [<xref rid="ref28" ref-type="bibr">28&#8211;30</xref>]. We utilized human-based probes from Agilent (SureSelect Human All Exon V6 panel) to capture exomes from four pairs of chimpanzee samples (tumor and normal tissue from the same individual). Enriched DNA from exome capture was then used to construct libraries, which were sequenced using a paired-end (2 &#215; 150&#160;bp) strategy on an Illumina platform, following Agilent&#8217;s protocols for whole-exome capture and library construction. For WGS, TruSeq DNA libraries were prepared and sequenced on the HiSeq platform following Illumina&#8217;s protocols, and 2 &#215; 150-bp paired- end reads were generated.</p></sec><sec id="sec12"><title>Somatic variant detection</title><sec id="sec13"><title>Mapping reads to the chimpanzee reference sequence</title><p>The chimpanzee reference genome (version Pan_tro_3.0/GCA_000001515.5), along with gene sequences and corresponding annotations, was downloaded from Ensembl (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://useast.ensembl.org/Pan_troglodytes/Info/Index" ext-link-type="uri">http://useast.ensembl.org/Pan_troglodytes/Info/Index</ext-link>). Raw reads were quality controlled and filtered using FastqMcf [<xref rid="ref31" ref-type="bibr">31</xref>]. We obtained an average of 13.97&#160;G base pairs of clean WES data for each sample (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S3</xref>). The clean reads were mapped to the reference genome using Burrows&#8211;Wheeler aligner (version 0.7.17) [<xref rid="ref32" ref-type="bibr">32</xref>] with default parameters.</p></sec><sec id="sec14"><title>Variant calling</title><p>Variant identification, including short insertions and deletions (indels), was performed using the Genome Analysis Toolkit [<xref rid="ref33" ref-type="bibr">33</xref>] (version 4.1.8.1) following the best practices for somatic mutation calling [<xref rid="ref34" ref-type="bibr">34</xref>, <xref rid="ref35" ref-type="bibr">35</xref>]. Specifically, MuTect2 [<xref rid="ref36" ref-type="bibr">36</xref>] was employed for this purpose. A PoN was created from WGS data of 65 wild-born [<xref rid="ref37" ref-type="bibr">37</xref>] (European Nucleotide Archive accession # PRJEB15086) and 39 captive-born chimpanzees (European Nucleotide Archive accession # PRJEB39475). These populations were chosen to improve variant calling accuracy by providing a comprehensive baseline of normal variants. Candidate somatic variants were generated using GATK MuTect2 (version 2.2) and subsequently filtered using the &#8220;FilterMutectCalls&#8221; function for orientation bias (&#8220;--ob-priors&#8221;) and read contamination (&#8220;--contamination-table&#8221;). Final variant filtering criteria included a minimum allele frequency of 0.05, a minimum median distance from the end of reads of 4, a minimum number of reads carrying variants required on both forward and reverse strands of 1, and a minimum of 2 unique reads supporting the alternate allele (&#8220;--min-allele-fraction 0.05 --min-median-read-position 4 --min-reads-per-strand 1 --unique-alt-read-count 2&#8221;).</p><p>To address the possibility of FFPE-related artifacts, a secondary pipeline was implemented incorporating duplicate marking with &#8220;MarkDuplicates,&#8221; base quality score recalibration using &#8220;BaseRecalibrator,&#8221; and application of recalibration via &#8220;ApplyBQSR.&#8221; This pipeline used a more stringent filtering strategy requiring a minimum allele frequency of 0.12, a minimum median distance from the end of reads of 8, a minimum of 6 unique reads supporting the alternate allele, and at least 3 variant-supporting reads from both the forward and reverse strands via &#8220;FilterMutectCalls&#8221; (&#8220;--min-allele-fraction 0.12 --min-median-read-position 8 --unique-alt-read-count 6 --min-reads-per-strand 3&#8221;). The resulting high-confidence (HQ) variant set from the FFPE-aware pipeline was used for mutation burden and spectrum comparisons discussed in this study.</p></sec><sec id="sec15"><title>Microsatellite variant detection</title><p>SMVs were identified using HipSTR [<xref rid="ref38" ref-type="bibr">38</xref>] (version: 0.7) with default stutter models (&#8220;--def-stutter-model&#8221;) and <italic toggle="yes">de novo</italic> allele generation. Candidate microsatellite variants were filtered using the following criteria: posterior probability for the genotype higher than 0.90, fraction of indels in reads mapping to the flanking regions of the microsatellite smaller than 0.15, fraction of reads containing stutter artifacts smaller than 0.15, log10 <italic toggle="yes">P</italic> value for the allele bias test higher than 2, and log10 <italic toggle="yes">P</italic> value for the Fisher strand bias test higher than 2 (&#8220;--min-call-qual 0.9 --max-call-flank-indel 0.15 --max-call-stutter 0.15 --min-call-allele-bias -2 --min-call-strand-bias -2&#8221;).</p></sec><sec id="sec16"><title>Variant annotation</title><p>All identified variants, including insertions, deletions, and microsatellites, were annotated using the Ensembl Variant Effect Predictor [<xref rid="ref39" ref-type="bibr">39</xref>] (version: 105.0).</p></sec><sec id="sec17"><title>Human datasets</title><p>Three human datasets were analyzed in this study (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S4</xref> and <xref rid="sup1" ref-type="supplementary-material">S5</xref>):</p><p>1) ICGC Dataset: Five HCC sample pairs with <italic toggle="yes">TSC2</italic> somatic mutation from Calderaro <italic toggle="yes">et&#160;al.</italic> [<xref rid="ref40" ref-type="bibr">40</xref>] (International Cancer Genome Consortium/ICGC sample ID: CHC1210, CHC1597, CHC1604, CHC2111, CHC798; referred to as Set ICGC).</p><p>2) TCGA+ Dataset: Five random HCC sample pairs from The Cancer Genome Atlas (TCGA; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://portal.gdc.cancer.gov/" ext-link-type="uri">https://portal.gdc.cancer.gov/</ext-link>) liver HCC project (TCGA-LIHC) with TSC2 somatic mutation (referred to as Set TCGA+).</p><p>3) TCGA- Dataset: Five random HCC sample pairs from TCGA-LIHC without <italic toggle="yes">TSC2</italic> somatic mutation (referred to as Set TCGA-). Sequencing data from the human datasets, including both tumor samples and matched normal samples (either blood-derived or solid tissue normals), were processed using the same pipeline as used for the chimpanzee data, with the exception that a PoN was not used for the human samples. Although the original ICGC selection criteria included samples reported to harbor <italic toggle="yes">TSC2</italic> mutations, in our re-analysis using a uniform variant-calling pipeline, the number of ICGC human samples meeting our internal mutation threshold for TSC2 was reduced to four. This discrepancy most likely reflects differences in variant-calling sensitivity, filtering thresholds and read-depth between the original ICGC study and our re-analysis.</p></sec><sec id="sec18"><title>Gene ontology <bold>enrichment and pathway analysis</bold></title><p>Functional enrichment analyses were conducted by importing the relevant gene lists into DAVID [<xref rid="ref41" ref-type="bibr">41</xref>] and Reactome [<xref rid="ref42" ref-type="bibr">42</xref>, <xref rid="ref43" ref-type="bibr">43</xref>]. Gene Ontology terms with a Benjamini&#8211;Hochberg adjusted <italic toggle="yes">P</italic> value of &lt;0.05 were considered significant.</p></sec></sec></sec><sec id="sec19"><title>RESULTS</title><p>We analyzed HCC samples and matching non-cancer samples from five adult chimpanzees through tissue immunostaining, whole genome sequencing (WGS), and whole exome sequencing (WES) in comparison with human HCCs.</p><sec id="sec20"><title>Chimpanzee HCC immunohistology</title><p>HCC is a highly heterogeneous tumor with variable etiology, and therefore molecular markers are commonly used to stratify human patients according to their clinical manifestation and outcomes [<xref rid="ref44" ref-type="bibr">44&#8211;46</xref>]. Expression levels of &#946;-catenin, <italic toggle="yes">ARID1A</italic>, <italic toggle="yes">TSC2</italic>, and <italic toggle="yes">FAP</italic> in paraffin-embedded chimpanzee tissues were assessed through our immunohistochemical analysis (<xref rid="f1" ref-type="fig">Fig. 1</xref>). The HCC samples, including the one metastasized to lymph node (<xref rid="f1" ref-type="fig">Fig. 1A</xref>), were characterized by either high or moderate levels of membranous &#946;-catenin expression (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>). While normal human hepatocytes do not express &#946;-catenin, it is expressed in HCC cells, accumulating predominantly in the membrane [<xref rid="ref47" ref-type="bibr">47</xref>]. The protein expression of <italic toggle="yes">ARID1A</italic> was observed in the nucleus and the cytoplasm, with its levels ranging from weak to moderate (<xref rid="f1" ref-type="fig">Fig. 1B</xref>). The AT-rich interactive domain 1A (<italic toggle="yes">ARID1A</italic>, also called <italic toggle="yes">BAF250A</italic>) is a key component of the mammalian SWI/SNF family regulating gene transcription through chromatin remodeling. The nuclear expression of <italic toggle="yes">ARID1A</italic> has been negatively associated with tumor size, pathological grade, tumor recurrence, and survival in human HCC patients [<xref rid="ref48" ref-type="bibr">48</xref>], while somatic mutations in <italic toggle="yes">ARID1A</italic> have been reported in HCC [<xref rid="ref49" ref-type="bibr">49</xref>]. Tuberous sclerosis complex 2 (TSC2) is a tumor suppressor gene that plays a critical role in regulating cell growth and proliferation [<xref rid="ref50" ref-type="bibr">50</xref>]. <italic toggle="yes">TSC2</italic> expression in the chimpanzee samples was mainly cytosolic with high immunostaining in four of the samples, including the metastatic lymph node tissue, and moderate in the remaining two tissue sections (<xref rid="f1" ref-type="fig">Fig. 1C</xref>). Inactivation of <italic toggle="yes">TSC2</italic>, either through mutation or deletion, can lead to uncontrolled cell growth and contribute to tumorigenesis [<xref rid="ref51" ref-type="bibr">51</xref>]. <italic toggle="yes">TSC2</italic> mutations in human HCC tissues have been associated with more aggressive tumor forms and higher recurrence rate [<xref rid="ref52" ref-type="bibr">52</xref>]. Fibroblast activation protein (<italic toggle="yes">FAP</italic>) expression was observed in the cytoplasm of cells and 50% of the stained tissues had high protein expression while the rest of tissues had low to moderate staining (<xref rid="f1" ref-type="fig">Fig. 1D</xref>). High <italic toggle="yes">FAP</italic> expression has been reported in HCC and was an independent risk factor for inferior clinical outcome in postsurgical patients [<xref rid="ref53" ref-type="bibr">53</xref>]. It is also validated as a prognostic biomarker [<xref rid="ref54" ref-type="bibr">54</xref>]. To further refine the stratification of HCC subtypes, we also used <italic toggle="yes">vimentin</italic> (<italic toggle="yes">VIM</italic>; <xref rid="f1" ref-type="fig">Fig. 1E</xref>) and <italic toggle="yes">TGF-&#946;</italic> (<xref rid="f1" ref-type="fig">Fig. 1F</xref>), typically associated with stromal fibrosis of the HCC tissues and cirrhosis, as well as scirrhous HCC subtype [<xref rid="ref55" ref-type="bibr">55</xref>]. Stromal cells secrete <italic toggle="yes">TGF-&#946;</italic> which activates fibroblasts and promotes initiation of HCC [<xref rid="ref56" ref-type="bibr">56</xref>]. Our results show that all chimpanzee HCC tissues (100%) exhibited strong positive staining for VIM, with high signal intensity (<xref rid="f1" ref-type="fig">Fig. 1E</xref>). In contrast, 50% of tissue specimens displayed low to moderate positivity for TGF-&#946; staining (<xref rid="f1" ref-type="fig">Fig. 1F</xref>).</p><fig position="float" id="f1" orientation="portrait"><label>Figure 1</label><caption><p>Immunohistochemical analysis of paraffin-embedded chimpanzee tissue specimens; representative photomicrographs of immunohistochemical staining of liver and metastatic lymph node (Met LN) chimpanzee (chimp#1-5) tissues with &#946;-catenin, ARID1A, TSC2, FAP, VIM, and TGF-&#946; antibodies; white arrows indicate positive protein signals; magnifications were 100&#215; (solid line, left panel) and 400&#215; (dashed line, right panel).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="eoaf038f1.jpg"/></fig></sec><sec id="sec21"><title>Somatic mutation landscape in chimpanzee HCC</title><sec id="sec22"><title>Overview of somatic variants</title><p>The sequence mapping rates ranged from 99.77% to 99.95%, with the percentages of paired-end reads uniquely aligned ranging from 94.19% to 99.28% (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S3</xref>). This high mapping rate indicates successful exome capture, ensuring the reliability of subsequent variant discovery procedures. A total of 452&#8201;277 somatic mutations were identified in the WGS sample (S1), with the majority being single nucleotide variants (SNVs; 317&#8201;632 or 70.23%; <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S6</xref>), and the remainder being indels (110&#8201;938 insertions and deletions). In the WES samples (S2, S3, S4, and S5), we found an average of 11&#8201;510 SNVs (ranging from 6813 to 14&#8201;701) and 13&#8201;615 indels (ranging from 6105 to 26&#8201;031; <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S6</xref>). Among the coding variants, we identified 1356 to 2897 non-synonymous mutations (missense and nonsense mutations) and 741 to 5341 frameshift mutations across the five samples (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S7</xref>).</p></sec><sec id="sec23"><title>Functional enrichment of somatic mutations</title><p>A total of 120 genes carrying at least one non-synonymous somatic mutation were found in all five chimpanzee HCC samples. Functional enrichment analysis of these 120 genes indicated significant involvement in ATP-dependent microtubule motor activity, dynein chain binding, ATPase activity, motor proteins, and microtubule-based movement (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S8</xref>). Additionally, 611 genes bearing non-synonymous somatic mutations were shared in at least four chimpanzee HCC samples. Notably, this included <italic toggle="yes">TSC2</italic> that was associated with the scirrhous subtype of HCC, a rare primary liver tumor with a prevalence in humans ranging from 0.2% to 4.6% [<xref rid="ref57" ref-type="bibr">57</xref>, <xref rid="ref58" ref-type="bibr">58</xref>]. Enrichment analysis of the 611 genes revealed additional significant functions related to ECM-receptor interaction, p53 binding, ATP-binding cassette transporters, and papillomavirus infection (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S9</xref>).</p></sec><sec id="sec34"><title>Comparative analysis of somatic mutations in chimpanzee and human HCC</title><p>Given the significance of <italic toggle="yes">TSC2</italic> mutations in determining the HCC subtype, we compared mutation patterns between chimpanzees and humans using two datasets (TCGA+ &amp; ICGC) of human HCC samples bearing mutant <italic toggle="yes">TSC2</italic> and one set (TCGA-) of human HCC samples without mutant <italic toggle="yes">TSC2</italic> as a control group. Each human dataset contained five sample pairs, randomly selected to match the limited sample size of the chimpanzee dataset. Only coding region mutations resulting in amino acid changes were included in the comparison. On average per sample, 5632 mutations were found in chimpanzee samples, while 275 mutations were found in TCGA+ samples and 96 mutations were found in ICGC samples (<xref rid="f2" ref-type="fig">Fig. 2A</xref>), despite comparable sequencing data amounts across datasets (average of 10.56&#160;GB for human datasets versus 13.97&#160;GB for chimpanzees; <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S4</xref>). Mutant allele frequency analysis showed that the vast majority of mutations exhibited frequencies below 40% across all four datasets, with a skew toward lower-frequency variants (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2</xref>). This distribution suggests a substantial degree of intra-tumor heterogeneity in both chimpanzee and human HCC samples. The predominance of low-frequency variants may partially reflect differences in tumor cellularity and sample purity, factors that are commonly encountered in tumor sequencing studies. SNVs accounted for an average of 47.78% of all mutations in chimpanzee samples, compared to 92.31% in human datasets (<xref rid="f2" ref-type="fig">Fig. 2B</xref>). The substantial number of somatic mutations observed in chimpanzee HCC samples, particularly indels, highlights potential differences in genomic stability and repair mechanisms between the two species. There were 10.5% more non-synonymous SNVs in humans compared with chimpanzees (61.7% non-synonymous in chimpanzee vs. 72.2% in human; Fisher&#8217;s exact test, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;2e-16; <xref rid="f2" ref-type="fig">Fig. 2C</xref>; <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S10</xref>). This result could imply differences in the evolutionary pressures faced by humans and chimpanzee HCC genomes, with either stronger positive selection or weaker purifying selection operating on HCC-related genes in humans relative to chimpanzees.</p><fig position="float" id="f2" orientation="portrait"><label>Figure 2</label><caption><p>Comparison of somatic variants among chimpanzee HCC samples and three human HCC datasets, all mutations that affect amino acids were included (A) or only SNVs were included (B); (C) synonymous (blue) to non-synonymous mutation (red) ratios in the chimpanzee and human HCC genomes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="eoaf038f2.jpg"/></fig></sec><sec id="sec25"><title>TSC2 mutations and associated somatic mutation profiles</title><p>
<italic toggle="yes">TSC2</italic> functions as a tumor suppressor and is a critical negative regulator of the pro-oncogenic mTOR signaling pathway [<xref rid="ref59" ref-type="bibr">59&#8211;61</xref>]. Eight non-synonymous somatic mutations were identified in <italic toggle="yes">TSC2</italic> across chimpanzee HCC samples, including five SNVs, two deletions, and one insertion (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S11</xref>). None of these mutations were located at the same positions across different samples, indicating diverse mutation sites within this tumor suppressor gene. A similar pattern was observed in the human datasets. In the ICGC set, four mutations were identified in <italic toggle="yes">TSC2</italic>, comprising two SNVs, one insertion, and one deletion. In the TCGA+ set, six mutations in <italic toggle="yes">TSC2</italic> were identified, including five deletions and one SNV. As with the chimpanzee samples, none of these mutations were located at the same positions, further highlighting the variability in mutation sites within TSC2.</p></sec><sec id="sec26"><title>Shared somatic mutations between chimpanzee and human HCC</title><p>A total of 93 somatic mutations were shared between at least two out of five chimpanzee HCC samples (<xref rid="f3" ref-type="fig">Fig. 3</xref>), including four genes with multiple shared mutations: <italic toggle="yes">BAG6</italic>, <italic toggle="yes">BIVM-ERCC5</italic>, <italic toggle="yes">MTMR3</italic>, and <italic toggle="yes">NUP153</italic> (<xref rid="TB1" ref-type="table">Table 1</xref>). Due to the lower number of mutations in human datasets, no mutation was shared among human samples. At the gene level, chimpanzee samples exhibited higher overlaps than human datasets, likely due to the higher number of mutations found in chimpanzee HCC samples (<xref rid="f3" ref-type="fig">Fig. 3</xref>).</p><fig position="float" id="f3" orientation="portrait"><label>Figure 3</label><caption><p>Gene-level overlap among samples with HCC-specific somatic mutations in chimpanzee and three human HCC datasets, ICGC, TCGA+ (with mutant TSC2), and TCGA+ (without mutant TSC2).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="eoaf038f3.jpg"/></fig><table-wrap position="float" id="TB1" orientation="portrait"><label>Table 1</label><caption><p>Genes with multiple shared mutations in chimpanzee HCC samples.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Gene</th><th align="left" rowspan="1" colspan="1">Mutations</th><th align="left" rowspan="1" colspan="1">AminoAcidChange</th><th align="left" rowspan="1" colspan="1">Samples</th><th align="left" rowspan="1" colspan="1">GeneDescription</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">BAG6</td><td align="left" rowspan="1" colspan="1">1879A&#8201;&gt;&#8201;G; 1895C&#8201;&gt;&#8201;T</td><td align="left" rowspan="1" colspan="1">Ala627Thr; Thr632Met</td><td align="left" rowspan="1" colspan="1">S2, S4</td><td align="left" rowspan="1" colspan="1">BAG Cochaperone 6</td></tr><tr><td align="left" rowspan="1" colspan="1">BIVM-ERCC5</td><td align="left" rowspan="1" colspan="1">2374&#160;T&#8201;&gt;&#8201;A; 4600G&#8201;&gt;&#8201;C</td><td align="left" rowspan="1" colspan="1">Ser792Thr; Gly1534Arg</td><td align="left" rowspan="1" colspan="1">S2, S3; S3, S5</td><td align="left" rowspan="1" colspan="1">Read-through transcription between the neighboring BIVM and ERCC5</td></tr><tr><td align="left" rowspan="1" colspan="1">MTMR3</td><td align="left" rowspan="1" colspan="1">2411A&#8201;&gt;&#8201;G; 2524A&#8201;&gt;&#8201;G</td><td align="left" rowspan="1" colspan="1">Asp804Gly; Met842Val</td><td align="left" rowspan="1" colspan="1">S3, S5</td><td align="left" rowspan="1" colspan="1">Myotubularin-related protein 3</td></tr><tr><td align="left" rowspan="1" colspan="1">NUP153</td><td align="left" rowspan="1" colspan="1">3158C&#8201;&gt;&#8201;T; 3148&#160;T&#8201;&gt;&#8201;C</td><td align="left" rowspan="1" colspan="1">Thr1053Ile; Phe1050Leu</td><td align="left" rowspan="1" colspan="1">S3, S5</td><td align="left" rowspan="1" colspan="1">Nucleoporin 153</td></tr></tbody></table></table-wrap><p>To investigate overlaps between chimpanzee and human HCC samples, we included only the two human datasets with TSC2 mutations (ICGC &amp; TCGA+). In addition to <italic toggle="yes">TSC2</italic>, we found 48 other genes with mutations present in chimpanzee and both human HCC datasets, including <italic toggle="yes">TTN, FAT4, TP53, SPEN, LRP1B</italic>, and <italic toggle="yes">STAG1</italic> (<xref rid="f4" ref-type="fig">Fig. 4</xref>; <xref rid="TB2" ref-type="table">Table 2</xref>; the full list of overlapping mutant genes is provided in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S12</xref>). The comparative analysis of somatic mutations in chimpanzees and humans reveals distinct mutation patterns, with chimpanzees exhibiting a higher proportion of indels. The presence of shared mutations and genes between species, particularly in genes implicated in cancer-related processes, underscores potential conserved mechanisms in HCC pathogenesis.</p><fig position="float" id="f4" orientation="portrait"><label>Figure 4</label><caption><p>Numbers of genes with HCC-specific somatic mutations, shared between chimpanzee two human datasets (ICGC and TCGA+).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="eoaf038f4.jpg"/></fig><table-wrap position="float" id="TB2" orientation="portrait"><label>Table 2</label><caption><p>Mutant genes shared among chimpanzee samples and human TSC2-positive datasets (TCGA+ and ICGC). The number indicates the count of samples in each dataset with HCC-specific mutations within each gene.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Gene</th><th align="left" rowspan="1" colspan="1">Chimpanzee</th><th align="left" rowspan="1" colspan="1">TCGA+</th><th align="left" rowspan="1" colspan="1">ICGC</th><th align="left" rowspan="1" colspan="1">GeneDescription</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">TSC2</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Tuberous sclerosis complex 2</td></tr><tr><td align="left" rowspan="1" colspan="1">TTN</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Titin</td></tr><tr><td align="left" rowspan="1" colspan="1">FAT4</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">FAT Atypical Cadherin 4</td></tr><tr><td align="left" rowspan="1" colspan="1">HYDIN</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">HYDIN Axonemal Central Pair Apparatus Protein</td></tr><tr><td align="left" rowspan="1" colspan="1">MYOM1</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Myomesin 1</td></tr><tr><td align="left" rowspan="1" colspan="1">PCDHGA4</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Protocadherin Gamma Subfamily A, 4</td></tr><tr><td align="left" rowspan="1" colspan="1">SPEN</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Spen Family Transcriptional Repressor</td></tr><tr><td align="left" rowspan="1" colspan="1">TP53</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Tumor Protein P53</td></tr><tr><td align="left" rowspan="1" colspan="1">UBR4</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Ubiquitin Protein Ligase E3 Component N-Recognin 4</td></tr><tr><td align="left" rowspan="1" colspan="1">ALMS1</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">ALMS1 Centrosome And Basal Body Associated Protein</td></tr><tr><td align="left" rowspan="1" colspan="1">ANK2</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Ankyrin 2</td></tr><tr><td align="left" rowspan="1" colspan="1">BDP1</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">B Double Prime 1</td></tr><tr><td align="left" rowspan="1" colspan="1">ENSPTRG00000044766</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">&#8211;</td></tr><tr><td align="left" rowspan="1" colspan="1">LRP1B</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">LDL Receptor Related Protein 1B</td></tr><tr><td align="left" rowspan="1" colspan="1">NCAPD3</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">Non-SMC Condensin II Complex Subunit D3</td></tr><tr><td align="left" rowspan="1" colspan="1">STAG1</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">STAG1 Cohesin Complex Component</td></tr><tr><td align="left" rowspan="1" colspan="1">UTRN</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">Utrophin</td></tr></tbody></table></table-wrap><p>To gain deeper insights into the mutational landscape and potential conservation of oncogenic drivers between chimpanzee and human HCC, we examined mutations in chimpanzee samples within a set of 23 recently identified HCC coding driver genes derived from a comprehensive analysis of 494 human HCC samples [<xref rid="ref62" ref-type="bibr">62</xref>]. Among these 23 coding driver genes, 18 harbored mutations in at least one chimpanzee HCC sample (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S13</xref>). Beyond <italic toggle="yes">TSC2</italic>, which has been implicated in HCC subtype differentiation, we identified three additional driver genes&#8212;<italic toggle="yes">ARID1A</italic>, <italic toggle="yes">BRD7</italic>, and <italic toggle="yes">FGA</italic>&#8212;that were recurrently mutated in four chimpanzee HCC samples.</p></sec></sec><sec id="sec27"><title>Microsatellite instability in chimpanzee and human HCC</title><p>Somatic microsatellite variants (SMVs) in cancer are indicative of microsatellite instability, often resulting from defects in the DNA mismatch repair system. On average, 793 SMVs were found in chimpanzee HCC samples (range: 280&#8211;1135), compared to 827, 662, 866 SMVs found in ICGC, TCGA+, and TCGA- datasets, respectively (<xref rid="f5" ref-type="fig">Fig. 5A</xref>). A slightly higher proportion of coding-affecting SMVs was found in chimpanzee samples (2%, <xref rid="f5" ref-type="fig">Fig. 5B</xref>) compared with human samples (1%, <xref rid="f5" ref-type="fig">Fig. 5B</xref>).</p><fig position="float" id="f5" orientation="portrait"><label>Figure 5</label><caption><p>Comparison of SMVs among chimpanzee HCC samples and three human HCC datasets, with all microsatellites (A) or microsatellites within coding region (B).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="eoaf038f5.jpg"/></fig></sec></sec><sec id="sec28"><title>DISCUSSION</title><p>HCC, the most common form of liver cancer, is genetically diverse and histologically variable, leading to its classification into several subtypes. The most common subtype, classical HCC subtype, frequently involves mutations in <italic toggle="yes">CTNNB1, TERT, TP53</italic>, and <italic toggle="yes">ARID1A</italic> genes [<xref rid="ref63" ref-type="bibr">63</xref>]. Fibrinogen alpha chain (<italic toggle="yes">FGA</italic>) has been determined to regulate HCC progression and metastasis [<xref rid="ref62" ref-type="bibr">62</xref>]. In the rare and aggressive Scirrhous-HCC subtype, which is characterized by dense fibrous stroma and small tumor nests, frequent Tuberous Sclerosis Complex 1 (<italic toggle="yes">TSC1</italic>)/Tuberous Sclerosis Complex 2 (<italic toggle="yes">TSC2</italic>) mutations have been prevalent [<xref rid="ref57" ref-type="bibr">57</xref>]. Interestingly, <italic toggle="yes">TSC2</italic> alterations are present in only 7% of human HCC patients [<xref rid="ref64" ref-type="bibr">64</xref>], whereas 80% of chimpanzees with HCC in our study possessed <italic toggle="yes">TSC2</italic> mutations. <italic toggle="yes">TSC2</italic> is a tumor suppressor gene that encodes the protein Tuberin complexing with Hamartin, the protein encoded by <italic toggle="yes">TSC1</italic>, and together they inhibit the mammalian target of rapamycin (mTOR) pathway, which is crucial for cell growth, metabolism, and proliferation. Clinical trials are currently testing the efficacy of mTOR inhibitors in HCC patients with <italic toggle="yes">TSC1</italic>/<italic toggle="yes">TSC2</italic> alterations [<xref rid="ref65" ref-type="bibr">65</xref>]. Variants in <italic toggle="yes">TSC2</italic> are associated with Tuberous Sclerosis Complex, a condition characterized by developmental issues and the growth of benign tumors in multiple body parts. Alterations in <italic toggle="yes">TSC2</italic> have been identified in 3.39% of all cancers, with a higher prevalence in lung adenocarcinoma, colon adenocarcinoma, breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, and high-grade ovarian serous adenocarcinoma [<xref rid="ref65" ref-type="bibr">65</xref>].</p><p>Dysregulated Wnt/&#946;-catenin signaling is implicated in ~40% of HCC cases [<xref rid="ref66" ref-type="bibr">66</xref>]. This pathway&#8217;s aberrant activation, often due to mutations in components like <italic toggle="yes">CTNNB1</italic> (encoding &#946;-catenin), plays a significant role in HCC pathogenesis. Notably, the tumor suppressor gene FAT Atypical Cadherin 4 (<italic toggle="yes">FAT4</italic>), which regulates Wnt/&#946;-catenin signaling, is mutated in all HCC cases in our chimpanzee study. FAT family genes are frequently mutated across multiple human cancer types and also found in HCC [<xref rid="ref67" ref-type="bibr">67</xref>]. In human HCC data collected from 379 patients in the TCGA database, alterations in FAT family genes occur with the following frequencies: <italic toggle="yes">FAT4</italic> in 5.74%, FAT Atypical Cadherin 2 (<italic toggle="yes">FAT2</italic>) in 5.46%, FAT Atypical Cadherin 1 (<italic toggle="yes">FAT1</italic>) in 6.28%, and FAT Atypical Cadherin 3 (<italic toggle="yes">FAT3</italic>) in 7.38% of cases [<xref rid="ref68" ref-type="bibr">68</xref>]. In our study, we found that <italic toggle="yes">FAT2</italic> was mutated in all chimpanzee HCC samples, <italic toggle="yes">FAT1</italic> and <italic toggle="yes">FAT3</italic> were mutated in 4 out of 5 samples. Of these FAT family genes, <italic toggle="yes">FAT4</italic> has the strongest association to HCC [<xref rid="ref69" ref-type="bibr">69</xref>] and these mutations likely contribute to the high expression of <italic toggle="yes">CTNNB1</italic> observed in the immunohistochemistry results and play a vital role in HCC initiation or progression.</p><p>Another gene of interest we discovered with a strong association to HCC, which was altered in two chimpanzee samples, is <italic toggle="yes">TP53</italic>. Known as the &#8220;guardian of the genome,&#8221; <italic toggle="yes">TP53</italic> regulates the cell cycle via checkpoints, induces cell cycle arrest when damage is detected, and can promote apoptosis. Beyond its central role in human cancer, <italic toggle="yes">TP53</italic> has also been a focus of comparative oncology: elephants, for instance, have evolved up to 20 functional copies of <italic toggle="yes">TP53</italic>, a genomic expansion thought to underlie their remarkable cancer resistance despite large body size and long lifespan [<xref rid="ref4" ref-type="bibr">4</xref>, <xref rid="ref5" ref-type="bibr">5</xref>]. <italic toggle="yes">TP53</italic> is the most frequently mutated gene in human cancers [<xref rid="ref70" ref-type="bibr">70</xref>] and has been shown to be altered in 32% of human HCC cases [<xref rid="ref68" ref-type="bibr">68</xref>]. Some studies suggest that the two most frequently mutated genes in HCC, <italic toggle="yes">TP53,</italic> and <italic toggle="yes">CTNNB1</italic>, occur mostly exclusively [<xref rid="ref71" ref-type="bibr">71</xref>, <xref rid="ref72" ref-type="bibr">72</xref>].</p><p>Not only does variation in cancer genome heterogeneity among species remain unknown, but the patterns of genomic heterogeneity and selective pressures underlying them across various cancer types in humans are also poorly understood [<xref rid="ref73" ref-type="bibr">73</xref>]. Human HCC-related genes are characterized by relatively high dN/dS values relative to other cancer types, exceeded only by pancreatic carcinoma, suggesting increased levels of adaptive evolution [<xref rid="ref73" ref-type="bibr">73</xref>]. While the SNV heterogeneity level in chimpanzee HCC is at least an order of magnitude higher, the signal of positive selection measured by non-synonymous SNVs is 10.5% stronger in humans. The observed differences in stability and potentially stronger positive selection pressures on human HCC genome may imply that evolutionarily HCC has been an earlier genomic challenge for humans than for chimpanzees. Chronic hepatitis B causes almost 40% of HCC in humans, and ancient HBV sequences have been found in fossilized remains of humans dating back to the Neolithic period around 7000&#160;years ago [<xref rid="ref74" ref-type="bibr">74</xref>]. Many ape species harbor endogenous HBV strains, but no evidence exists to suggest that these strains can infect humans [<xref rid="ref75" ref-type="bibr">75</xref>, <xref rid="ref76" ref-type="bibr">76</xref>], implying a higher virulence of human HBV strains. We also note that while our dataset indicates a greater non-synonymous excess in human compared with chimpanzee HCCs, we did not perform formal gene- or site-level evolutionary modeling (such as dNdScv [<xref rid="ref77" ref-type="bibr">77</xref>] or cancereffectsizeR [<xref rid="ref78" ref-type="bibr">78</xref>]) owing to the small chimpanzee cohort and thus limited statistical power. Future work with expanded chimpanzee cohorts and deeper mutation datasets will be required to apply robust selection-inference models and validate inter-species differences in evolutionary pressure.</p><p>The unique genetic alterations identified in the chimpanzee HCC genomes, particularly the high prevalence of <italic toggle="yes">TSC2</italic> mutations, suggest species-specific pathways of oncogenesis. The role of <italic toggle="yes">TSC2</italic> and the mTOR signaling pathway in cancer progression is well-established in humans, and the high frequency of these mutations in chimpanzee samples may indicate a parallel, yet distinct, evolutionary adaptation in this species. This finding opens up new avenues for research into how similar oncogenic pathways may be differentially regulated across species and how these differences could inform targeted therapies. Understanding these variations could lead to the identification of novel therapeutic targets and biomarkers that are not apparent when focusing solely on human cancer genomics.</p><p>To address a possibility that the elevated somatic mutation burden observed in chimpanzee tumors is attributable to formalin-fixed paraffin-embedded (FFPE)-related artifacts rather than innate causes, we implemented a more stringent variant filtering pipeline (applied through FilterMutectCalls; see Materials and Methods) specifically designed to mitigate known sources of FFPE-induced noise, resulting in a high-confidence variants set (Chimpanzee-HQ). Even after applying these stringent filters, chimpanzee tumors retained a substantially higher number of somatic mutations (average of 1742) compared to human tumors (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S6</xref>). Within the human cohort, mutation counts did not substantially differ between FFPE-preserved (TCGA+) and non-FFPE samples (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S4</xref>), suggesting that fixation method alone does not account for the observed interspecies disparity. We recognize that FFPE preservation can introduce context-dependent artifacts, particularly C&#8201;&gt;&#8201;T transitions arising from cytosine deamination and low-frequency variants near read ends. Although the stringent filtering substantially reduced the overall variant count, the qualitative mutational spectrum remained consistent (Supplementary <xref rid="sup1" ref-type="supplementary-material">Fig. S3A</xref> and <xref rid="sup1" ref-type="supplementary-material">B</xref>), supporting the interpretation that the remaining variants likely reflect underlying biological processes rather than purely technical noise. Yet, we acknowledge that FFPE-associated effects cannot be entirely excluded, particularly in the absence of matched fresh-frozen chimpanzee tumor samples. The current data indicate that the elevated mutational burden in chimpanzee HCC cannot be fully attributed to FFPE effects and likely reflects true differences in tumor evolution and genome instability between species.</p><p>The chimpanzee reference genome and catalog of population polymorphisms remain less comprehensive than their human counterparts, which may result in some residual germline variants to be misclassified as somatic mutations, despite the use of a panel of normals (PoN) derived from a larger chimpanzee population. Although the mutational spectrum remained qualitatively stable after stringent filtering (Supplementary <xref rid="sup1" ref-type="supplementary-material">Fig. S3</xref>), we cannot entirely exclude the possibility that a fraction of germline variants or reference-related artifacts contributed to the elevated mutation burden. Nevertheless, the magnitude of the difference in mutation counts between chimpanzee and human HCCs, even under conservative assumptions and rigorous filtering, suggests that these technical factors alone are unlikely to fully account for the observed disparity. We therefore interpret this as evidence of a genuine increase in somatic mutation burden in chimpanzee HCC.</p><p>It is tempting to speculate that the observed divergence in mutational patterns between chimpanzee and human HCCs likely reflects broader life-history and evolutionary differences between the two species. Humans differ from chimpanzees in several key life-history traits, including markedly longer lifespan, delayed sexual maturity, higher birth weights, longer gestation, slower juvenile growth, and an extended post-reproductive lifespan [<xref rid="ref79" ref-type="bibr">79</xref>]. An adolescent growth spurt, long thought to be unique to humans, seems to occur in chimpanzees as well [<xref rid="ref80" ref-type="bibr">80</xref>]. Chimpanzees, in contrast, mature earlier, experience higher adult mortality, and reproduce more frequently but have longer mother&#8211;infant dependency periods. These contrasts may contribute to distinct evolutionary trade-offs between somatic maintenance, reproductive output, and cancer susceptibility. In humans, extended longevity and delayed maturity intensify selection for genome maintenance and tumor suppression over longer timescales, whereas in chimpanzees, faster turnover and shorter lifespan may favor more transient but effective early-life defenses. Human fitness is further decoupled from longevity by post-reproductive survival and cooperative care, while chimpanzees forfeit potential lifetime fertility through adult mortality attrition [<xref rid="ref79" ref-type="bibr">79</xref>]. Variation in infant mortality and fertility rates drives demographic differences between species, underscoring that cancer resistance, too, evolves within these same life-history constraints.</p><p>However, we also recognize that the small cohort size (<italic toggle="yes">n</italic>&#8201;=&#8201;5) used in our study limits generalizability. As such, we view this study as exploratory and hypothesis-generating. Access to chimpanzee materials is increasingly limited, as these animals are retired from biomedical research and naturally exhibit relatively low cancer incidence. Consequently, future studies&#8212;where feasible&#8212;with larger chimpanzee cohorts and expanded germline variant resources will be required to validate these findings and to further clarify species-specific differences in mutational processes and selective pressures between humans and other primates.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>eoaf038_supplement_files</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="eoaf038_supplement_files.zip" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="eoaf038-ack"><title>Acknowledgements</title><p>This investigation used resources that were provided by Edward Via College of Osteopathic Medicine and supported by the Southwest National Primate Research Center grant P51 OD011133 from the Office of Research Infrastructure Programs, National Institutes of Health. We thank the members of the SNPRC Pathology Core and the Veterinary Resources Staff.</p></ack><sec id="sec29"><title>Author Contributions</title><p>Lin Kang (Data curation [equal], Formal analysis [lead], Investigation [equal], Methodology [equal], Software [equal], Validation [equal]), Katarzyna Michalak (Investigation [equal], Methodology [equal]), Robin Varghese (Investigation [equal], Writing&#8212;original draft [equal]), Ramu Anandakrishnan (Conceptualization [supporting], Investigation [supporting], Methodology [equal]), Edward J. Dick (Conceptualization [equal], Resources [equal]), Zakaria Abd Elmageed (Conceptualization [equal], Formal analysis [equal], Investigation [equal], Methodology [equal], Writing&#8212;original draft [equal]), and Pawel Michalak (Conceptualization [lead], Investigation [equal], Methodology [equal], Project administration [lead], Resources [equal], Supervision [equal], Writing&#8212;original draft [equal])</p><p>
<italic toggle="yes">Conflict of interest</italic>: None declared.</p></sec><sec id="sec30"><title>Funding</title><p>None declared.</p></sec><sec sec-type="data-availability" id="sec31"><title>Data availability</title><p>All sequence data have been deposited at NCBI SRA with accession # PRJNA1150607.</p></sec><sec id="sec32"><title>Declaration of Generative AI and AI-Assisted Technologies</title><p>None were used.</p></sec><ref-list id="bib1"><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Albuquerque</surname> &#160;<given-names>TAF</given-names></string-name>, <string-name name-style="western"><surname>Drummond do Val</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Doherty</surname> &#160;<given-names>A</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>From humans to hydra: patterns of cancer across the tree of life</article-title>. <source><italic toggle="yes">Biol Rev Camb Philos Soc</italic></source> &#160;<year>2018</year>;<volume>93</volume>:<fpage>1715</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1111/brv.12415</pub-id><pub-id pub-id-type="pmid">29663630</pub-id><pub-id pub-id-type="pmcid">PMC6055669</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Peto</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hiatt</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Watson</surname> &#160;<given-names>J</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Origins of human cancer</article-title>. <source><italic toggle="yes">by Hiatt, HH, Watson</italic></source> &#160;<year>1977</year>;<volume>3</volume>:<fpage>1403</fpage>.</mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Maciak</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Michalak</surname> &#160;<given-names>P</given-names></string-name></person-group>. <article-title>Cell size and cancer: a new solution to Peto&#8217;s paradox?</article-title> &#160;<source><italic toggle="yes">Evol Appl</italic></source> &#160;<year>2015</year>;<volume>8</volume>:<fpage>2</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/eva.12228</pub-id><pub-id pub-id-type="pmid">25667599</pub-id><pub-id pub-id-type="pmcid">PMC4310577</pub-id></mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sulak</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Fong</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Mika</surname> &#160;<given-names>K</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>TP53 copy number expansion is associated with the evolution of increased body size and an enhanced DNA damage response in elephants</article-title>. <source><italic toggle="yes">Elife</italic></source> &#160;<year>2016</year>;<volume>5</volume>. <pub-id pub-id-type="doi">10.7554/eLife.11994</pub-id><pub-id pub-id-type="pmcid">PMC5061548</pub-id><pub-id pub-id-type="pmid">27642012</pub-id></mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abegglen</surname> &#160;<given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Caulin</surname> &#160;<given-names>AF</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname> &#160;<given-names>A</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Potential mechanisms for cancer resistance in elephants and comparative cellular response to DNA damage in humans</article-title>. <source><italic toggle="yes">JAMA</italic></source> &#160;<year>2015</year>;<volume>314</volume>:<fpage>1850</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2015.13134</pub-id><pub-id pub-id-type="pmid">26447779</pub-id><pub-id pub-id-type="pmcid">PMC4858328</pub-id></mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Keane</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Semeiks</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Webb</surname> &#160;<given-names>AE</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Insights into the evolution of longevity from the bowhead whale genome</article-title>. <source><italic toggle="yes">Cell Rep</italic></source> &#160;<year>2015</year>;<volume>10</volume>:<fpage>112</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2014.12.008</pub-id><pub-id pub-id-type="pmid">25565328</pub-id><pub-id pub-id-type="pmcid">PMC4536333</pub-id></mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname> &#160;<given-names>EB</given-names></string-name>, <string-name name-style="western"><surname>Fang</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Fushan</surname> &#160;<given-names>AA</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Genome sequencing reveals insights into physiology and longevity of the naked mole rat</article-title>. <source><italic toggle="yes">Nature</italic></source> &#160;<year>2011</year>;<volume>479</volume>:<fpage>223</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nature10533nature10533</pub-id> [pii]<pub-id pub-id-type="pmid">21993625</pub-id><pub-id pub-id-type="pmcid">PMC3319411</pub-id></mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fang</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Nevo</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Han</surname> &#160;<given-names>L</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Genome-wide adaptive complexes to underground stresses in blind mole rats Spalax</article-title>. <source><italic toggle="yes">Nat Commun</italic></source> &#160;<year>2014</year>;<volume>5</volume>:<fpage>3966</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms4966</pub-id><pub-id pub-id-type="pmid">24892994</pub-id></mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Seim</surname> &#160;<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Fang</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname> &#160;<given-names>Z</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Genome analysis reveals insights into physiology and longevity of the Brandt&#8217;s bat <italic toggle="yes">Myotis brandtii</italic></article-title>. <source><italic toggle="yes">Nat Commun</italic></source> &#160;<year>2013</year>;<volume>4</volume>:<fpage>2212</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms3212</pub-id><pub-id pub-id-type="pmid">23962925</pub-id><pub-id pub-id-type="pmcid">PMC3753542</pub-id></mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kang</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Michalak</surname> &#160;<given-names>P</given-names></string-name></person-group>. <article-title>The evolution of cancer-related genes in hominoids</article-title>. <source><italic toggle="yes">J Mol Evol</italic></source> &#160;<year>2015</year>;<volume>80</volume>:<fpage>37</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1007/s00239-014-9649-5</pub-id><pub-id pub-id-type="pmid">25249249</pub-id></mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Nielsen</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Bustamante</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Clark</surname> &#160;<given-names>AG</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>A scan for positively selected genes in the genomes of humans and chimpanzees</article-title>. <source><italic toggle="yes">PLoS Biol</italic></source> &#160;<year>2005</year>;<volume>3</volume>:<fpage>e170</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pbio.0030170</pub-id><pub-id pub-id-type="pmid">15869325</pub-id><pub-id pub-id-type="pmcid">PMC1088278</pub-id></mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pavlicek</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Noskov</surname> &#160;<given-names>VN</given-names></string-name>, <string-name name-style="western"><surname>Kouprina</surname> &#160;<given-names>N</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition</article-title>. <source><italic toggle="yes">Hum Mol Genet</italic></source> &#160;<year>2004</year>;<volume>13</volume>:<fpage>2737</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddh301</pub-id><pub-id pub-id-type="pmid">15385441</pub-id></mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dumont</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Frank</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Moisan</surname> &#160;<given-names>AM</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2</article-title>. <source><italic toggle="yes">Biochim Biophys Acta</italic></source> &#160;<year>2004</year>;<volume>1679</volume>:<fpage>230</fpage>&#8211;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbaexp.2004.07.001</pub-id><pub-id pub-id-type="pmid">15358515</pub-id></mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ding</surname> &#160;<given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Larson</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Rivas</surname> &#160;<given-names>G</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Strong signature of natural selection within an FHIT intron implicated in prostate cancer risk</article-title>. <source><italic toggle="yes">PLoS One</italic></source> &#160;<year>2008</year>;<volume>3</volume>:<fpage>e3533</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0003533</pub-id><pub-id pub-id-type="pmid">18953408</pub-id><pub-id pub-id-type="pmcid">PMC2568805</pub-id></mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Suntsova</surname> &#160;<given-names>MV</given-names></string-name>, <string-name name-style="western"><surname>Buzdin</surname> &#160;<given-names>AA</given-names></string-name></person-group>. <article-title>Differences between human and chimpanzee genomes and their implications in gene expression, protein functions and biochemical properties of the two species</article-title>. <source><italic toggle="yes">BMC Genomics</italic></source> &#160;<year>2020</year>;<volume>21</volume>:<fpage>535</fpage>. <pub-id pub-id-type="doi">10.1186/s12864-020-06962-8</pub-id><pub-id pub-id-type="pmid">32912141</pub-id><pub-id pub-id-type="pmcid">PMC7488140</pub-id></mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cagan</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Baez-Ortega</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Brzozowska</surname> &#160;<given-names>N</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Somatic mutation rates scale with lifespan across mammals</article-title>. <source><italic toggle="yes">Nature</italic></source> &#160;<year>2022</year>;<volume>604</volume>:<fpage>517</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-022-04618-z</pub-id><pub-id pub-id-type="pmid">35418684</pub-id><pub-id pub-id-type="pmcid">PMC9021023</pub-id></mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vincze</surname> &#160;<given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Colchero</surname> &#160;<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Lemaitre</surname> &#160;<given-names>JF</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Cancer risk across mammals</article-title>. <source><italic toggle="yes">Nature</italic></source> &#160;<year>2022</year>;<volume>601</volume>:<fpage>263</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-04224-5</pub-id><pub-id pub-id-type="pmid">34937938</pub-id><pub-id pub-id-type="pmcid">PMC8755536</pub-id></mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Brown</surname> &#160;<given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname> &#160;<given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Dick</surname> &#160;<given-names>EJ</given-names> &#160;<suffix>Jr</suffix></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Neoplasia in the chimpanzee (Pan spp.)</article-title>. <source><italic toggle="yes">J Med Primatol</italic></source> &#160;<year>2009</year>;<volume>38</volume>:<fpage>137</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0684.2008.00321.x</pub-id><pub-id pub-id-type="pmid">19367738</pub-id><pub-id pub-id-type="pmcid">PMC2893876</pub-id></mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lapin</surname> &#160;<given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Yakovleva</surname> &#160;<given-names>LA</given-names></string-name></person-group>. <article-title>Spontaneous and experimental malignancies in non-human primates</article-title>. <source><italic toggle="yes">J Med Primatol</italic></source> &#160;<year>2014</year>;<volume>43</volume>:<fpage>100</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1111/jmp.12098</pub-id><pub-id pub-id-type="pmid">24392944</pub-id></mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>European Association for the Study of the Liver</collab></person-group>. <article-title>EASL clinical practice guidelines: management of hepatocellular carcinoma</article-title>. <source><italic toggle="yes">J Hepatol</italic></source> &#160;<year>2018</year>;<volume>69</volume>:<fpage>182</fpage>&#8211;<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2018.03.019</pub-id><pub-id pub-id-type="pmid">29628281</pub-id></mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Muchmore</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Popper</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Peterson</surname> &#160;<given-names>DA</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Non-A, non-B hepatitis-related hepatocellular carcinoma in a chimpanzee</article-title>. <source><italic toggle="yes">J Med Primatol</italic></source> &#160;<year>1988</year>;<volume>17</volume>:<fpage>235</fpage>&#8211;<lpage>46</lpage>.<pub-id pub-id-type="pmid">3148034</pub-id></mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abe</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kagei</surname> &#160;<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Teramura</surname> &#160;<given-names>Y</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Hepatocellular carcinoma associated with chronic <italic toggle="yes">Schistosoma mansoni</italic> infection in a chimpanzee</article-title>. <source><italic toggle="yes">J Med Primatol</italic></source> &#160;<year>1993</year>;<volume>22</volume>:<fpage>237</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">8230173</pub-id></mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wieland</surname> &#160;<given-names>SF</given-names></string-name></person-group>. <article-title>The chimpanzee model for hepatitis B virus infection</article-title>. <source>Cold Spring Harb Perspect Med</source> &#160;<year>2015</year>;<volume>5</volume>:1&#8211;19. <pub-id pub-id-type="doi">10.1101/cshperspect.a021469</pub-id><pub-id pub-id-type="pmcid">PMC4448699</pub-id><pub-id pub-id-type="pmid">26033082</pub-id></mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bukh</surname> &#160;<given-names>J</given-names></string-name></person-group>. <article-title>A critical role for the chimpanzee model in the study of hepatitis C</article-title>. <source><italic toggle="yes">Hepatology</italic></source> &#160;<year>2004</year>;<volume>39</volume>:<fpage>1469</fpage>&#8211;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1002/hep.20268</pub-id><pub-id pub-id-type="pmid">15185284</pub-id></mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Gaballa</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname> &#160;<given-names>HEA</given-names></string-name>, <string-name name-style="western"><surname>Mahmoud</surname> &#160;<given-names>MO</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Exosomes-mediated transfer of Itga2 promotes migration and invasion of prostate cancer cells by inducing epithelial-mesenchymal transition</article-title>. <source><italic toggle="yes">Cancers (Basel)</italic></source> &#160;<year>2020</year>;<volume>12</volume>:1&#8211;20. <pub-id pub-id-type="doi">10.3390/cancers12082300</pub-id><pub-id pub-id-type="pmcid">PMC7466113</pub-id><pub-id pub-id-type="pmid">32824235</pub-id></mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abd Elmageed</surname> &#160;<given-names>ZY</given-names></string-name>, <string-name name-style="western"><surname>Sholl</surname> &#160;<given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Tsumagari</surname> &#160;<given-names>K</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer</article-title>. <source><italic toggle="yes">Surgery</italic></source> &#160;<year>2017</year>;<volume>161</volume>:<fpage>1122</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.surg.2016.06.081</pub-id><pub-id pub-id-type="pmid">27919446</pub-id></mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Abd Elmageed</surname> &#160;<given-names>ZY</given-names></string-name>, <string-name name-style="western"><surname>Moroz</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Srivastav</surname> &#160;<given-names>SK</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>High circulating estrogens and selective expression of ERbeta in prostate tumors of Americans: implications for racial disparity of prostate cancer</article-title>. <source><italic toggle="yes">Carcinogenesis</italic></source> &#160;<year>2013</year>;<volume>34</volume>:<fpage>2017</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1093/carcin/bgt156</pub-id><pub-id pub-id-type="pmid">23658372</pub-id><pub-id pub-id-type="pmcid">PMC3765045</pub-id></mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chan</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yao</surname> &#160;<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Howard</surname> &#160;<given-names>TD</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Efficiency of whole-exome sequencing in old world and new world primates using human capture reagents</article-title>. <source><italic toggle="yes">J Med Primatol</italic></source> &#160;<year>2021</year>;<volume>50</volume>:<fpage>176</fpage>&#8211;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1111/jmp.12524</pub-id><pub-id pub-id-type="pmid">33876458</pub-id><pub-id pub-id-type="pmcid">PMC8407272</pub-id></mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jin</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>He</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ferguson</surname> &#160;<given-names>B</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>An effort to use human-based exome capture methods to analyze chimpanzee and macaque exomes</article-title>. <source><italic toggle="yes">PLoS One</italic></source> &#160;<year>2012</year>;<volume>7</volume>:<fpage>e40637</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0040637</pub-id><pub-id pub-id-type="pmid">22848389</pub-id><pub-id pub-id-type="pmcid">PMC3407233</pub-id></mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vallender</surname> &#160;<given-names>EJ</given-names></string-name></person-group>. <article-title>Expanding whole exome resequencing into non-human primates</article-title>. <source><italic toggle="yes">Genome Biol</italic></source> &#160;<year>2011</year>;<volume>12</volume>:<fpage>R87</fpage>. <pub-id pub-id-type="doi">10.1186/gb-2011-12-9-r87</pub-id><pub-id pub-id-type="pmid">21917143</pub-id><pub-id pub-id-type="pmcid">PMC3308050</pub-id></mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Aronesty</surname> &#160;<given-names>E</given-names></string-name></person-group>. <article-title>Comparison of sequencing utility programs</article-title>. <source><italic toggle="yes">The Open Bioinformatics Journal</italic></source> &#160;<year>2013</year>;<volume>7</volume>:<fpage>1</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.2174/1875036201307010001</pub-id></mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Li</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Durbin</surname> &#160;<given-names>R</given-names></string-name></person-group>. <article-title>Fast and accurate long-read alignment with Burrows&#8211;Wheeler transform</article-title>. <source><italic toggle="yes">Bioinformatics</italic></source> &#160;<year>2010</year>;<volume>26</volume>:<fpage>589</fpage>&#8211;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1093/bioinformatics/btp698</pub-id><pub-id pub-id-type="pmid">20080505</pub-id><pub-id pub-id-type="pmcid">PMC2828108</pub-id></mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McKenna</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hanna</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Banks</surname> &#160;<given-names>E</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</article-title>. <source><italic toggle="yes">Genome Res</italic></source> &#160;<year>2010</year>;<volume>20</volume>:<fpage>1297</fpage>&#8211;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1101/gr.107524.110</pub-id><pub-id pub-id-type="pmid">20644199</pub-id><pub-id pub-id-type="pmcid">PMC2928508</pub-id></mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Koboldt</surname> &#160;<given-names>DC</given-names></string-name></person-group>. <article-title>Best practices for variant calling in clinical sequencing</article-title>. <source><italic toggle="yes">Genome Med</italic></source> &#160;<year>2020</year>;<volume>12</volume>:<fpage>91</fpage>. <pub-id pub-id-type="doi">10.1186/s13073-020-00791-w</pub-id><pub-id pub-id-type="pmid">33106175</pub-id><pub-id pub-id-type="pmcid">PMC7586657</pub-id></mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Van der Auwera</surname> &#160;<given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Carneiro</surname> &#160;<given-names>MO</given-names></string-name>, <string-name name-style="western"><surname>Hartl</surname> &#160;<given-names>C</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>From FastQ data to high confidence variant calls: the genome analysis toolkit best practices pipeline</article-title>. <source><italic toggle="yes">Curr Protoc Bioinformatics</italic></source> &#160;<year>2013</year>;<volume>43</volume>:<fpage>11 10 1</fpage>&#8211;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1002/0471250953.bi1110s43</pub-id><pub-id pub-id-type="pmcid">PMC4243306</pub-id><pub-id pub-id-type="pmid">25431634</pub-id></mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cibulskis</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Lawrence</surname> &#160;<given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Carter</surname> &#160;<given-names>SL</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples</article-title>. <source><italic toggle="yes">Nat Biotechnol</italic></source> &#160;<year>2013</year>;<volume>31</volume>:<fpage>213</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.2514</pub-id><pub-id pub-id-type="pmid">23396013</pub-id><pub-id pub-id-type="pmcid">PMC3833702</pub-id></mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><prefix>de</prefix> &#160;<surname>Manuel</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kuhlwilm</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Frandsen</surname> &#160;<given-names>P</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Chimpanzee genomic diversity reveals ancient admixture with bonobos</article-title>. <source><italic toggle="yes">Science</italic></source> &#160;<year>2016</year>;<volume>354</volume>:<fpage>477</fpage>&#8211;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1126/science.aag2602</pub-id><pub-id pub-id-type="pmid">27789843</pub-id><pub-id pub-id-type="pmcid">PMC5546212</pub-id></mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Willems</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Zielinski</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Yuan</surname> &#160;<given-names>J</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Genome-wide profiling of heritable and de novo STR variations</article-title>. <source><italic toggle="yes">Nat Methods</italic></source> &#160;<year>2017</year>;<volume>14</volume>:<fpage>590</fpage>&#8211;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.4267</pub-id><pub-id pub-id-type="pmid">28436466</pub-id><pub-id pub-id-type="pmcid">PMC5482724</pub-id></mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>McLaren</surname> &#160;<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Gil</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hunt</surname> &#160;<given-names>SE</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>The Ensembl variant effect predictor</article-title>. <source><italic toggle="yes">Genome Biol</italic></source> &#160;<year>2016</year>;<volume>17</volume>:<fpage>122</fpage>. <pub-id pub-id-type="doi">10.1186/s13059-016-0974-4</pub-id><pub-id pub-id-type="pmid">27268795</pub-id><pub-id pub-id-type="pmcid">PMC4893825</pub-id></mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Calderaro</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Couchy</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Imbeaud</surname> &#160;<given-names>S</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification</article-title>. <source><italic toggle="yes">J Hepatol</italic></source> &#160;<year>2017</year>;<volume>67</volume>:<fpage>727</fpage>&#8211;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2017.05.014</pub-id><pub-id pub-id-type="pmid">28532995</pub-id></mixed-citation></ref><ref id="ref41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang da</surname> &#160;<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Sherman</surname> &#160;<given-names>BT</given-names></string-name>, <string-name name-style="western"><surname>Lempicki</surname> &#160;<given-names>RA</given-names></string-name></person-group>. <article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title>. <source><italic toggle="yes">Nat Protoc</italic></source> &#160;<year>2009</year>;<volume>4</volume>:<fpage>44</fpage>&#8211;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2008.211nprot.2008.211</pub-id> [pii]<pub-id pub-id-type="pmid">19131956</pub-id></mixed-citation></ref><ref id="ref42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Haw</surname> &#160;<given-names>R</given-names></string-name></person-group>. <article-title>Functional interaction network construction and analysis for disease discovery</article-title>. <source><italic toggle="yes">Methods Mol Biol</italic></source> &#160;<year>2017</year>;<volume>1558</volume>:<fpage>235</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4939-6783-4_11</pub-id><pub-id pub-id-type="pmid">28150241</pub-id></mixed-citation></ref><ref id="ref43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fabregat</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Sidiropoulos</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Viteri</surname> &#160;<given-names>G</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Reactome pathway analysis: a high-performance in-memory approach</article-title>. <source><italic toggle="yes">BMC Bioinformatics</italic></source> &#160;<year>2017</year>;<volume>18</volume>:<fpage>142</fpage>. <pub-id pub-id-type="doi">10.1186/s12859-017-1559-2</pub-id><pub-id pub-id-type="pmid">28249561</pub-id><pub-id pub-id-type="pmcid">PMC5333408</pub-id></mixed-citation></ref><ref id="ref44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Suresh</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Dhanasekaran</surname> &#160;<given-names>R</given-names></string-name></person-group>. <article-title>Implications of genetic heterogeneity in hepatocellular cancer</article-title>. <source><italic toggle="yes">Adv Cancer Res</italic></source> &#160;<year>2022</year>;<volume>156</volume>:<fpage>103</fpage>&#8211;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/bs.acr.2022.01.007</pub-id><pub-id pub-id-type="pmid">35961697</pub-id><pub-id pub-id-type="pmcid">PMC10321863</pub-id></mixed-citation></ref><ref id="ref45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Schulze</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Imbeaud</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Letouze</surname> &#160;<given-names>E</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets</article-title>. <source><italic toggle="yes">Nat Genet</italic></source> &#160;<year>2015</year>;<volume>47</volume>:<fpage>505</fpage>&#8211;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3252</pub-id><pub-id pub-id-type="pmid">25822088</pub-id><pub-id pub-id-type="pmcid">PMC4587544</pub-id></mixed-citation></ref><ref id="ref46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Llovet</surname> &#160;<given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Montal</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Sia</surname> &#160;<given-names>D</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Molecular therapies and precision medicine for hepatocellular carcinoma</article-title>. <source><italic toggle="yes">Nat Rev Clin Oncol</italic></source> &#160;<year>2018</year>;<volume>15</volume>:<fpage>599</fpage>&#8211;<lpage>616</lpage>. <pub-id pub-id-type="doi">10.1038/s41571-018-0073-4</pub-id><pub-id pub-id-type="pmid">30061739</pub-id><pub-id pub-id-type="pmcid">PMC12452113</pub-id></mixed-citation></ref><ref id="ref47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tien</surname> &#160;<given-names>LT</given-names></string-name>, <string-name name-style="western"><surname>Ito</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nakao</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Expression of beta-catenin in hepatocellular carcinoma</article-title>. <source><italic toggle="yes">World J Gastroenterol</italic></source> &#160;<year>2005</year>;<volume>11</volume>:<fpage>2398</fpage>&#8211;<lpage>401</lpage>. <pub-id pub-id-type="doi">10.3748/wjg.v11.i16.2398</pub-id><pub-id pub-id-type="pmid">15832407</pub-id><pub-id pub-id-type="pmcid">PMC4305624</pub-id></mixed-citation></ref><ref id="ref48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Meng</surname> &#160;<given-names>GX</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname> &#160;<given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname> &#160;<given-names>LJ</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>The somatic mutational landscape and role of the ARID1A gene in hepatocellular carcinoma</article-title>. <source><italic toggle="yes">Heliyon</italic></source> &#160;<year>2023</year>;<volume>9</volume>:<fpage>e14307</fpage>. <pub-id pub-id-type="doi">10.1016/j.heliyon.2023.e14307</pub-id><pub-id pub-id-type="pmid">36950649</pub-id><pub-id pub-id-type="pmcid">PMC10025035</pub-id></mixed-citation></ref><ref id="ref49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Guichard</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Amaddeo</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Imbeaud</surname> &#160;<given-names>S</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma</article-title>. <source><italic toggle="yes">Nat Genet</italic></source> &#160;<year>2012</year>;<volume>44</volume>:<fpage>694</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2256</pub-id><pub-id pub-id-type="pmid">22561517</pub-id><pub-id pub-id-type="pmcid">PMC3819251</pub-id></mixed-citation></ref><ref id="ref50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Urakami</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tsuchiya</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Orimoto</surname> &#160;<given-names>K</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Overexpression of members of the AP-1 transcriptional factor family from an early stage of renal carcinogenesis and inhibition of cell growth by AP-1 gene antisense oligonucleotides in the Tsc2 gene mutant (Eker) rat model</article-title>. <source><italic toggle="yes">Biochem Biophys Res Commun</italic></source> &#160;<year>1997</year>;<volume>241</volume>:<fpage>24</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1006/bbrc.1997.7731</pub-id><pub-id pub-id-type="pmid">9405228</pub-id></mixed-citation></ref><ref id="ref51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Giannikou</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Malinowska</surname> &#160;<given-names>IA</given-names></string-name>, <string-name name-style="western"><surname>Pugh</surname> &#160;<given-names>TJ</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Whole exome sequencing identifies TSC1/TSC2 biallelic loss as the primary and sufficient driver event for renal angiomyolipoma development</article-title>. <source><italic toggle="yes">PLoS Genet</italic></source> &#160;<year>2016</year>;<volume>12</volume>:<fpage>e1006242</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pgen.1006242</pub-id><pub-id pub-id-type="pmid">27494029</pub-id><pub-id pub-id-type="pmcid">PMC4975391</pub-id></mixed-citation></ref><ref id="ref52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ho</surname> &#160;<given-names>DWH</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname> &#160;<given-names>LK</given-names></string-name>, <string-name name-style="western"><surname>Chiu</surname> &#160;<given-names>YT</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication</article-title>. <source><italic toggle="yes">Gut</italic></source> &#160;<year>2017</year>;<volume>66</volume>:<fpage>1496</fpage>&#8211;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1136/gutjnl-2016-312734</pub-id><pub-id pub-id-type="pmid">27974549</pub-id><pub-id pub-id-type="pmcid">PMC5530480</pub-id></mixed-citation></ref><ref id="ref53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zou</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname> &#160;<given-names>B</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>The expression of FAP in hepatocellular carcinoma cells is induced by hypoxia and correlates with poor clinical outcomes</article-title>. <source><italic toggle="yes">J Cancer</italic></source> &#160;<year>2018</year>;<volume>9</volume>:<fpage>3278</fpage>&#8211;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.7150/jca.25775</pub-id><pub-id pub-id-type="pmid">30271487</pub-id><pub-id pub-id-type="pmcid">PMC6160687</pub-id></mixed-citation></ref><ref id="ref54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dziadek</surname> &#160;<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kraxner</surname> &#160;<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Cheng</surname> &#160;<given-names>WY</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies</article-title>. <source><italic toggle="yes">Front Immunol</italic></source> &#160;<year>2024</year>;<volume>15</volume>:<fpage>1352615</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2024.1352615</pub-id><pub-id pub-id-type="pmid">38558814</pub-id><pub-id pub-id-type="pmcid">PMC10981271</pub-id></mixed-citation></ref><ref id="ref55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Seok</surname> &#160;<given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Na</surname> &#160;<given-names>DC</given-names></string-name>, <string-name name-style="western"><surname>Woo</surname> &#160;<given-names>HG</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition</article-title>. <source><italic toggle="yes">Hepatology</italic></source> &#160;<year>2012</year>;<volume>55</volume>:<fpage>1776</fpage>&#8211;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1002/hep.25570</pub-id><pub-id pub-id-type="pmid">22234953</pub-id></mixed-citation></ref><ref id="ref56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wu</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Ding</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname> &#160;<given-names>C</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development</article-title>. <source><italic toggle="yes">Hepatology</italic></source> &#160;<year>2012</year>;<volume>56</volume>:<fpage>2255</fpage>&#8211;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1002/hep.26007</pub-id><pub-id pub-id-type="pmid">22898879</pub-id></mixed-citation></ref><ref id="ref57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Calderaro</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Couchy</surname> &#160;<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Imbeaud</surname> &#160;<given-names>S</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification</article-title>. <source><italic toggle="yes">J Hepatol</italic></source> &#160;<year>2017</year>;<volume>67</volume>:<fpage>727</fpage>&#8211;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.jhep.2017.05.014</pub-id><pub-id pub-id-type="pmid">28532995</pub-id></mixed-citation></ref><ref id="ref58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jernigan</surname> &#160;<given-names>PL</given-names></string-name>, <string-name name-style="western"><surname>Wima</surname> &#160;<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hanseman</surname> &#160;<given-names>DJ</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Natural history and treatment trends in hepatocellular carcinoma subtypes: insights from a national cancer registry</article-title>. <source><italic toggle="yes">J Surg Oncol</italic></source> &#160;<year>2015</year>;<volume>112</volume>:<fpage>872</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1002/jso.24083</pub-id><pub-id pub-id-type="pmid">26603598</pub-id></mixed-citation></ref><ref id="ref59"><label>59.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name name-style="western"><surname>Northrup</surname> &#160;<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Koenig</surname> &#160;<given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Pearson</surname> &#160;<given-names>DA</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<part-title>Tuberous sclerosis complex</part-title>. In: <person-group person-group-type="editor"><string-name name-style="western"><surname>Adam</surname> &#160;<given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Feldman</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Mirzaa</surname> &#160;<given-names>GM</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> (eds.), <source><italic toggle="yes">GeneReviews((R))</italic></source>. <publisher-loc>Seattle, WA</publisher-loc>, <year>1993</year>. University of Washington, Seattle.</mixed-citation></ref><ref id="ref60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jones</surname> &#160;<given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Shyamsundar</surname> &#160;<given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname> &#160;<given-names>MW</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis</article-title>. <source><italic toggle="yes">Am J Hum Genet</italic></source> &#160;<year>1999</year>;<volume>64</volume>:<fpage>1305</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1086/302381</pub-id><pub-id pub-id-type="pmid">10205261</pub-id><pub-id pub-id-type="pmcid">PMC1377866</pub-id></mixed-citation></ref><ref id="ref61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Feliciano</surname> &#160;<given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Lin</surname> &#160;<given-names>TV</given-names></string-name>, <string-name name-style="western"><surname>Hartman</surname> &#160;<given-names>NW</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits</article-title>. <source><italic toggle="yes">Int J Dev Neurosci</italic></source> &#160;<year>2013</year>;<volume>31</volume>:<fpage>667</fpage>&#8211;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijdevneu.2013.02.008</pub-id><pub-id pub-id-type="pmid">23485365</pub-id><pub-id pub-id-type="pmcid">PMC3830611</pub-id></mixed-citation></ref><ref id="ref62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname> &#160;<given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Xue</surname> &#160;<given-names>R</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Deep whole-genome analysis of 494 hepatocellular carcinomas</article-title>. <source><italic toggle="yes">Nature</italic></source> &#160;<year>2024</year>;<volume>627</volume>:<fpage>586</fpage>&#8211;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-024-07054-3</pub-id><pub-id pub-id-type="pmid">38355797</pub-id></mixed-citation></ref><ref id="ref63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab></person-group>. <article-title>Comprehensive and integrative genomic characterization of hepatocellular carcinoma</article-title>. <source><italic toggle="yes">Cell</italic></source> &#160;<year>2017</year>;<volume>169</volume>:<fpage>1327</fpage>&#8211;<lpage>1341 e23</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.05.046</pub-id><pub-id pub-id-type="pmid">28622513</pub-id><pub-id pub-id-type="pmcid">PMC5680778</pub-id></mixed-citation></ref><ref id="ref64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Consortium APG</collab></person-group>. <article-title>AACR project GENIE: powering precision medicine through an international consortium</article-title>. <source><italic toggle="yes">Cancer Discov</italic></source> &#160;<year>2017</year>;<volume>7</volume>:<fpage>818</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0151</pub-id><pub-id pub-id-type="pmid">28572459</pub-id><pub-id pub-id-type="pmcid">PMC5611790</pub-id></mixed-citation></ref><ref id="ref65"><label>65.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><string-name name-style="western"><surname>Kwiatkowski</surname> &#160;<given-names>D.</given-names></string-name></person-group> &#160;<source>A Phase II Trial of Everolimus for Cancer Patients with Inactivating Mutations in TSC1 or TSC2 or Activating MTOR Mutations</source>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT02201212" ext-link-type="uri">https://clinicaltrials.gov/study/NCT02201212</ext-link> (<comment>2020, date last accessed</comment>). The National Center for Biotechnology Information, Bethesda, MD.</mixed-citation></ref><ref id="ref66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Xu</surname> &#160;<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname> &#160;<given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname> &#160;<given-names>Y</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Beta-catenin signaling in hepatocellular carcinoma</article-title>. <source><italic toggle="yes">J Clin Invest</italic></source> &#160;<year>2022</year>;<volume>132</volume>:1&#8211;10. <pub-id pub-id-type="doi">10.1172/JCI154515</pub-id><pub-id pub-id-type="pmcid">PMC8843739</pub-id><pub-id pub-id-type="pmid">35166233</pub-id></mixed-citation></ref><ref id="ref67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morris</surname> &#160;<given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>Ramaswami</surname> &#160;<given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Chan</surname> &#160;<given-names>TA</given-names></string-name></person-group>. <article-title>The FAT epidemic: a gene family frequently mutated across multiple human cancer types</article-title>. <source><italic toggle="yes">Cell Cycle</italic></source> &#160;<year>2013</year>;<volume>12</volume>:<fpage>1011</fpage>&#8211;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.4161/cc.24305</pub-id><pub-id pub-id-type="pmid">23493187</pub-id><pub-id pub-id-type="pmcid">PMC3646852</pub-id></mixed-citation></ref><ref id="ref68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cerami</surname> &#160;<given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Gao</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Dogrusoz</surname> &#160;<given-names>U</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</article-title>. <source><italic toggle="yes">Cancer Discov</italic></source> &#160;<year>2012</year>;<volume>2</volume>:<fpage>401</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0095</pub-id><pub-id pub-id-type="pmid">22588877</pub-id><pub-id pub-id-type="pmcid">PMC3956037</pub-id></mixed-citation></ref><ref id="ref69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Huang</surname> &#160;<given-names>FY</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname> &#160;<given-names>DK</given-names></string-name>, <string-name name-style="western"><surname>Mak</surname> &#160;<given-names>LY</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>FAT4 loss initiates hepatocarcinogenesis through the switching of canonical to noncanonical WNT signaling pathways</article-title>. <source><italic toggle="yes">Hepatol Commun</italic></source> &#160;<year>2023</year>;<volume>7</volume>:1&#8211;15. <pub-id pub-id-type="doi">10.1097/HC9.0000000000000338</pub-id><pub-id pub-id-type="pmcid">PMC10984662</pub-id><pub-id pub-id-type="pmid">38055646</pub-id></mixed-citation></ref><ref id="ref70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chen</surname> &#160;<given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname> &#160;<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Su</surname> &#160;<given-names>W</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Mutant p53 in cancer: from molecular mechanism to therapeutic modulation</article-title>. <source><italic toggle="yes">Cell Death Dis</italic></source> &#160;<year>2022</year>;<volume>13</volume>:<fpage>974</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-022-05408-1</pub-id><pub-id pub-id-type="pmid">36400749</pub-id><pub-id pub-id-type="pmcid">PMC9674619</pub-id></mixed-citation></ref><ref id="ref71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Torbenson</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kannangai</surname> &#160;<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Abraham</surname> &#160;<given-names>S</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Concurrent evaluation of p53, beta-catenin, and alpha-fetoprotein expression in human hepatocellular carcinoma</article-title>. <source><italic toggle="yes">Am J Clin Pathol</italic></source> &#160;<year>2004</year>;<volume>122</volume>:<fpage>377</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1309/YH0H-3FKY-M4RM-U1JF</pub-id><pub-id pub-id-type="pmid">15362367</pub-id></mixed-citation></ref><ref id="ref72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Biterge Sut</surname> &#160;<given-names>B</given-names></string-name></person-group>. <article-title>Computational analysis of TP53 vs. CTNNB1 mutations in hepatocellular carcinoma suggests distinct cancer subtypes with differential gene expression profiles and chromatin states</article-title>. <source><italic toggle="yes">Comput Biol Chem</italic></source> &#160;<year>2020</year>;<volume>89</volume>:<fpage>107404</fpage>. <pub-id pub-id-type="doi">10.1016/j.compbiolchem.2020.107404</pub-id><pub-id pub-id-type="pmid">33096424</pub-id></mixed-citation></ref><ref id="ref73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dentro</surname> &#160;<given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Leshchiner</surname> &#160;<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Haase</surname> &#160;<given-names>K</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes</article-title>. <source><italic toggle="yes">Cell</italic></source> &#160;<year>2021</year>;<volume>184</volume>:<fpage>2239</fpage>&#8211;<lpage>2254 e39</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2021.03.009</pub-id><pub-id pub-id-type="pmid">33831375</pub-id><pub-id pub-id-type="pmcid">PMC8054914</pub-id></mixed-citation></ref><ref id="ref74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Krause-Kyora</surname> &#160;<given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Susat</surname> &#160;<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Key</surname> &#160;<given-names>FM</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Neolithic and medieval virus genomes reveal complex evolution of hepatitis B</article-title>. <source><italic toggle="yes">Elife</italic></source> &#160;<year>2018</year>;<fpage>7</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.36666</pub-id><pub-id pub-id-type="pmcid">PMC6008052</pub-id><pub-id pub-id-type="pmid">29745896</pub-id></mixed-citation></ref><ref id="ref75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Robertson</surname> &#160;<given-names>BH</given-names></string-name>, <string-name name-style="western"><surname>Margolis</surname> &#160;<given-names>HS</given-names></string-name></person-group>. <article-title>Primate hepatitis B viruses&#8212;genetic diversity, geography and evolution</article-title>. <source><italic toggle="yes">Rev Med Virol</italic></source> &#160;<year>2002</year>;<volume>12</volume>:<fpage>133</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1002/rmv.348</pub-id><pub-id pub-id-type="pmid">11987138</pub-id></mixed-citation></ref><ref id="ref76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Locarnini</surname> &#160;<given-names>SA</given-names></string-name>, <string-name name-style="western"><surname>Littlejohn</surname> &#160;<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Yuen</surname> &#160;<given-names>LKW</given-names></string-name></person-group>. <article-title>Origins and evolution of the primate hepatitis B virus</article-title>. <source><italic toggle="yes">Front Microbiol</italic></source> &#160;<year>2021</year>;<volume>12</volume>:<fpage>653684</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2021.653684</pub-id><pub-id pub-id-type="pmid">34108947</pub-id><pub-id pub-id-type="pmcid">PMC8180572</pub-id></mixed-citation></ref><ref id="ref77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Martincorena</surname> &#160;<given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Raine</surname> &#160;<given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Gerstung</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>Universal patterns of selection in cancer and somatic tissues</article-title>. <source><italic toggle="yes">Cell</italic></source> &#160;<year>2017</year>;<volume>171</volume>:<fpage>1029</fpage>&#8211;<lpage>1041 e21</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.09.042</pub-id><pub-id pub-id-type="pmid">29056346</pub-id><pub-id pub-id-type="pmcid">PMC5720395</pub-id></mixed-citation></ref><ref id="ref78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mandell</surname> &#160;<given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Cannataro</surname> &#160;<given-names>VL</given-names></string-name>, <string-name name-style="western"><surname>Townsend</surname> &#160;<given-names>JP</given-names></string-name></person-group>. <article-title>Estimation of neutral mutation rates and quantification of somatic variant selection using cancereffectsizeR</article-title>. <source><italic toggle="yes">Cancer Res</italic></source> &#160;<year>2023</year>;<volume>83</volume>:<fpage>500</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-22-1508</pub-id><pub-id pub-id-type="pmid">36469362</pub-id><pub-id pub-id-type="pmcid">PMC9929515</pub-id></mixed-citation></ref><ref id="ref79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Davison</surname> &#160;<given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Gurven</surname> &#160;<given-names>MD</given-names></string-name></person-group>. <article-title>Human uniqueness? Life history diversity among small-scale societies and chimpanzees</article-title>. <source><italic toggle="yes">PLoS One</italic></source> &#160;<year>2021</year>;<volume>16</volume>:<fpage>e0239170</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0239170</pub-id><pub-id pub-id-type="pmid">33617556</pub-id><pub-id pub-id-type="pmcid">PMC7899333</pub-id></mixed-citation></ref><ref id="ref80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sandel</surname> &#160;<given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Negrey</surname> &#160;<given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Arponen</surname> &#160;<given-names>M</given-names></string-name> &#160;<etal>et&#160;al.</etal></person-group> &#160;<article-title>The evolution of the adolescent growth spurt: urinary biomarkers of bone turnover in wild chimpanzees (Pan troglodytes)</article-title>. <source><italic toggle="yes">J Hum Evol</italic></source> &#160;<year>2023</year>;<volume>177</volume>:<fpage>103341</fpage>. <pub-id pub-id-type="doi">10.1016/j.jhevol.2023.103341</pub-id><pub-id pub-id-type="pmid">36905703</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>